VYNE Therapeutics Inc.

DRS filed

VYNE Therapeutics Inc. filed a draft registration statement (DRS) for a proposed merger with Yarrow Bioscience, Inc., involving the exchange of Yarrow shares for VYNE stock and warrants. The merger includes a reverse stock split, new stock incentive plans, and shareholder approvals for governance changes. The filing outlines terms for converting Yarrow equity, adjusting VYNE options, and listing the combined company on Nasdaq under a new ticker.

EFFECT effective

VYNE Therapeutics Inc. filed a Notice of Effectiveness for its S-3 registration statement on March 14, 2024, following a previous filing on November 22, 2023. The current filing confirms the effectiveness of the registration, but no substantive updates or changes to the company's operations, financials, or risk profile are disclosed in the provided text.

EFFECT effective

VYNE Therapeutics Inc. filed an S-3 registration statement with the SEC, which became effective on November 22, 2023. This filing follows a prior S-3 registration from May 14, 2021, with the same CIK and company name. The current filing likely relates to a subsequent securities offering, though specific details about the offering's scope or purpose are not provided in the notice of effectiveness.

EFFECT effective

The current filing for VYNE Therapeutics Inc. is a Form S-3, indicating a secondary offering, effective May 14, 2021. The previous filing, for Menlo Therapeutics Inc., was a Form S-4 from January 7, 2020, typically used for mergers or acquisitions. The filings pertain to different companies, limiting direct comparability.

EFFECT effective

The filing reports the effectiveness of a Form S-4 registration statement for Menlo Therapeutics Inc. on January 7, 2020, following a previous S-3 filing in February 2019. The document confirms regulatory approval but provides minimal substantive details beyond standard administrative information.

EFFECT effective

The filing confirms the effectiveness of VYNE Therapeutics Inc.'s registration statement on February 12, 2019, for an S-3 form. This follows a previous 424B4 prospectus for an IPO, indicating the company has completed its initial public offering process. The document outlines key details of the offering, including underwriting terms and use of proceeds.

424B4 priced

Menlo Therapeutics Inc. is conducting its initial public offering (IPO) by issuing 7,000,000 shares of common stock at $17.00 per share, with proceeds totaling $119 million before expenses. The offering includes underwriting discounts of $1.19 per share, and the company plans to use the net proceeds for development, commercialization, and general corporate purposes. The stock is listed on the Nasdaq Global Select Market under 'MNLO.' The filing highlights risks related to clinical trial outcomes, regulatory approvals, and dependence on a single product candidate, serlopitant.

EFFECT effective

VYNE Therapeutics Inc. (formerly Menlo Therapeutics, Inc.) filed an S-1 registration statement for its initial public offering (IPO), effective January 24, 2018. The filing details the registration of 7,475,000 shares of common stock, including an underwriter option to purchase an additional 975,000 shares. The company, an emerging growth company, focuses on developing serlopitant for treating pruritus and refractory chronic cough. The IPO aimed to raise up to $127 million, with proceeds intended for clinical trials, commercialization, and general operations.

S-1/A amended

Menlo Therapeutics Inc. is conducting an initial public offering (IPO) to register 6,500,000 shares of common stock at an estimated price range of $16.00 to $17.00 per share. The company, an emerging growth company, focuses on developing serlopitant for pruritus associated with dermatologic conditions and refractory chronic cough. The filing includes details on underwriting terms, use of proceeds, and risk factors related to clinical trial outcomes, regulatory approvals, and market competition.

8-A12B effective

VYNE Therapeutics Inc. filed Form 8-A12B to register its common stock for listing on NASDAQ. The filing incorporates by reference the capital stock description from its earlier S-1/A registration statement, which outlined its business focus on developing serlopitant for pruritus and refractory chronic cough. The 8-A12B does not include underwriting details or risk factors, relying instead on prior disclosures.

S-1/A amended

VYNE Therapeutics Inc. is conducting its initial public offering (IPO) to raise capital for the development and commercialization of serlopitant, a potential treatment for pruritus associated with dermatologic conditions and refractory chronic cough. The company expects to list on the Nasdaq Global Select Market under the ticker 'MNLO' and has secured commitments from institutional investors to purchase up to $40 million in shares. The filing highlights ongoing Phase 2 and Phase 3 clinical trials for serlopitant, with key efficacy data anticipated in 2018-2020. The company remains an emerging growth company, benefiting from reduced reporting requirements.

S-1/A amended

VYNE Therapeutics Inc. is conducting an initial public offering (IPO) to raise capital for the development and commercialization of serlopitant, a potential treatment for pruritus (itch) associated with dermatologic conditions and refractory chronic cough. The company is seeking to list on the Nasdaq Global Market under the symbol 'MNLO' and has engaged underwriters for the offering. The filing highlights the company's focus on late-stage clinical trials, with anticipated Phase 2 data in 2018 and Phase 3 trials for prurigo nodularis. The IPO aims to fund ongoing research, regulatory submissions, and commercialization efforts.

S-1 filed

VYNE Therapeutics Inc. is conducting its initial public offering (IPO) to raise capital for the development and commercialization of serlopitant, a potential treatment for pruritus (itch) associated with dermatologic conditions like atopic dermatitis, psoriasis, and prurigo nodularis, as well as refractory chronic cough. The company has completed Phase 2 trials showing statistically significant improvements in pruritus and plans Phase 3 trials for prurigo nodularis, with potential regulatory submissions for multiple indications by 2020. The IPO aims to fund further clinical development, commercialization, and operational growth.

DRS/A amended

Menlo Therapeutics Inc. is conducting an initial public offering (IPO) for its common stock, aiming to raise capital to advance the development and commercialization of serlopitant, a potential treatment for pruritus (itch) associated with dermatologic conditions and refractory chronic cough. The company is in late-stage clinical development, with Phase 2 trial results showing statistically significant improvements in pruritus. The IPO includes plans for Phase 3 trials and potential regulatory approvals for multiple indications.

DRS filed

VYNE Therapeutics Inc. filed a DRS on October 30, 2017, for an initial public offering (IPO) of its common stock. The company is developing serlopitant, a neurokinin 1 receptor inhibitor, for treating pruritus (itch) associated with dermatologic conditions and refractory chronic cough. Phase 2 trials demonstrated statistically significant pruritus reduction, with plans for Phase 3 trials in prurigo nodularis and ongoing studies for atopic dermatitis, psoriasis, and chronic cough. The filing highlights the company's status as an emerging growth company, limited operating history, and reliance on a single drug candidate.